Enterovirus Infections: Clinical Trials

68 trials for Enterovirus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

53 completed, 4 recruiting, 4 terminated, 3 unknown. 68 Phase 2, 10 Phase 1, 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 268Completed 53, Recruiting 4, Terminated 4, Unknown 3, Active not recruiting 2, Withdrawn 2
Phase 110Completed 6, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 39Completed 5, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow Enterovirus Infections: new trials by email Literature Review of Enterovirus Infections trials Research Report on Enterovirus Infections

Trials (filtered) newest first · largest first

All 68 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed
Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis
Phase 1 / Phase 2RecruitingInstitute of Medical Biology, Chinese Academy of Medical Sciences3802026-10-112026-10-23
Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 2 (nOPV2), Placebo (Sterile Water) - Poliomyelitis
Phase 2RecruitingPATH6752025-11-112026-01-09
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus
Phase 2 / Phase 3Active not recruitingLG Chem11862025-05-302026-09-03
Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell), Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell), High-dose tetravalent inactivated enterovirus vaccine (Vero cell) ) - Hand, Foot, and Mouth Disease (HFMD), Herpangina
Phase 1 / Phase 2CompletedSinovac Biotech Co., Ltd5522025-01-152026-03-04
A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers
Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose, VLP-Polio medium dose, VLP-Polio high dose - Poliomyelitis
Phase 1 / Phase 2Active not recruitingCanSino Biologics Inc.4802024-12-192026-08-06
Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines
Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3) - Poliomyelitis
Phase 1 / Phase 2RecruitingPATH24002024-11-202025-06-03
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus
Phase 2UnknownLG Chem3362024-10-022024-10-01
Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3) - Poliomyelitis
Phase 2RecruitingPATH15322023-12-052026-05-11
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Vapendavir, Placebo - COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection
Phase 2CompletedAltesa Biosciences, Inc.522023-11-202025-09-30
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated - Hand, Foot and Mouth Disease, Herpangina
Phase 1 / Phase 2CompletedSinovac Biotech Co., Ltd7442023-09-202026-06-26
Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1), Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1) - Poliomyelitis
Phase 2CompletedPATH22322023-03-272026-09-25
Immunogenicity nOPV2 With and Without bOPV
Novel monovalent oral poliovirus vaccine type 2 (nOPV2), Bivalent oral poliovirus vaccine (bOPV) - Poliomyelitis
Phase 2CompletedCenters for Disease Control and Prevention7952021-02-082024-10-04
Clinical Trial of Novel OPV2 Vaccine
novel oral polio type 2 vaccine (nOPV2), Placebo - Poliomyelitis
Phase 2CompletedInternational Centre for Diarrhoeal Disease Research, Bangladesh3302020-09-212022-08-30
Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally
Inactivated poliovirus vaccine in reduced doses - Polio
Phase 2CompletedInstituto Nacional de Saúde, Mozambique3822020-08-062024-01-31
Safety & Immunogenicity of Enterovirus Type 71 Vaccine in Healthy Adults and Children 6-71months
Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell) - Hand Foot & Mouth Disease
Phase 1 / Phase 2CompletedInternational Centre for Diarrhoeal Disease Research, Bangladesh4302019-12-242021-02-02
Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants
DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus
Phase 2UnknownLG Chem3362019-11-012019-09-06
Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option
EPs® 7630 - Hand, Foot, and Mouth Disease
Phase 2 / Phase 3CompletedEskisehir Osmangazi University2402019-06-012024-04-09
A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine
nOPV2 (monovalent oral polio vaccine) - Poliomyelitis
Phase 2CompletedFidec Corporation10252018-12-042024-01-19
A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
Novel OPV2 candidate 1, Novel OPV2 candidate 2, Placebo - Poliomyelitis
Phase 2CompletedPierre Van Damme2502018-10-222021-10-15
The Diabetes Virus Detection and Intervention Trial
Ribavirin + Pleconaril, Placebos - Type1 Diabetes Mellitus, Enterovirus
Phase 2CompletedOslo University Hospital962018-08-302021-04-08

Showing 20 of 68. Sign in to see all of them.

Narrower conditions

Poliomyelitis (43)  ·  Tetanus (21)  ·  Diphtheria (20)  ·  Hepatitis B (18)  ·  Haemophilus Infections (16)  ·  Whooping Cough (11)  ·  Hand, Foot and Mouth Disease (9)  ·  Hepatitis A (6)  ·  Herpangina (3)  ·  Infections (3)  ·  Postpoliomyelitis Syndrome (3)  ·  Diabetes Mellitus, Type 1 (2)  ·  RNA Virus Infections (2)  ·  Virus Diseases (2)

Broader conditions

Picornaviridae Infections (67)  ·  RNA Virus Infections (66)  ·  Virus Diseases (66)  ·  Infections (65)  ·  Central Nervous System Diseases (47)  ·  Central Nervous System Infections (47)  ·  Nervous System Diseases (47)  ·  Neuroinflammatory Diseases (47)  ·  Myelitis (46)  ·  Neuromuscular Diseases (46)  ·  Spinal Cord Diseases (46)  ·  Digestive System Diseases (23)  ·  Hepatitis (23)  ·  Hepatitis, Viral, Human (23)

Interventions

Poliovirus Vaccine, Inactivated (9)  ·  diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (9)  ·  Adjuvants, Pharmaceutic (4)  ·  13-valent pneumococcal vaccine (3)  ·  Vaccines, Combined (3)  ·  Hepatitis A Vaccines (2)  ·  Immunoglobulins, Intravenous (2)  ·  Pneumococcal Vaccines (2)  ·  Rabies Vaccines (2)  ·  Tetanus Toxoid (2)  ·  Vaccines (2)  ·  pleconaril (2)  ·  10-valent pneumococcal vaccine (1)  ·  Acetaminophen (1)  ·  Chickenpox Vaccine (1)

Sponsors

GlaxoSmithKline (11)  ·  Sanofi Pasteur, a Sanofi Company (6)  ·  LG Chem (5)  ·  Sinovac Biotech Co., Ltd (5)  ·  PATH (4)  ·  Institute of Medical Biology, Chinese Academy of Medical Sciences (3)  ·  Centers for Disease Control and Prevention (2)  ·  Enimmune Corporation (2)  ·  International Centre for Diarrhoeal Disease Research, Bangladesh (2)  ·  Jiangsu Province Centers for Disease Control and Prevention (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Oslo University Hospital (2)  ·  Ain Shams University (1)  ·  Altesa Biosciences, Inc. (1)  ·  Bayer (1)

Countries

China (11)  ·  United States (6)  ·  Bangladesh (5)  ·  Canada (5)  ·  Panama (5)  ·  Poland (5)  ·  Finland (4)  ·  Germany (4)  ·  Philippines (4)  ·  Dominican Republic (3)  ·  Belgium (2)  ·  France (2)  ·  Italy (2)  ·  Norway (2)  ·  Spain (2)

Top investigators

Yan-pin Li, MD (2)  ·  Amanda Wilkinson, PhD (1)  ·  Andre Vertruyen, MD (1)  ·  Bridget Wills, MD (1)  ·  Dang D Anh, PhD (1)  ·  Edison Alberto, MD (1)  ·  Edna Viegas, MD,PhD (1)  ·  Elisabeth Farbu, MD, PhD (1)  ·  Fengcai Zhu, Master (1)  ·  Glacus S Brito, MD (1)  ·  Ingrid Kromann (1)  ·  Jingsi Yang (1)

Results publications

PMID 22153001, PMID 28340322, PMID 32867698, PMID 40318674, PMID 20856164, PMID 21372751, PMID 22158682, PMID 23241989, PMID 23372725, PMID 24346596, PMID 25043278, PMID 25540274, PMID 26419198, PMID 26719058, PMID 26896318, PMID 27686833, PMID 27815383, PMID 28419204, PMID 28454674, PMID 29304199, PMID 30249424, PMID 31399275, PMID 31438878, PMID 33308427, PMID 33308429, PMID 33351072, PMID 33867179, PMID 36332645, PMID 36495882, PMID 37178706, PMID 38218668, PMID 38832001

NIH funding

2008 (1), 2009 (1), 2014 (1), 2015 (1), 2018 (1)